Compare McCormick & Company, Incorporated (MKC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Recursion Pharmaceuticals Inc — how do they compare? McCormick & Company, Incorporated trades at $51.43 (market cap $13.96B), while Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B). The key difference: McCormick & Company, Incorporated is far larger — about 7.5× Recursion Pharmaceuticals Inc's market cap, and McCormick & Company, Incorporated pays a 3.7% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MKC | RXRX | |
|---|---|---|
Market Cap | $13.96B | $1.86B |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $6.79 |
52-Week Low | $45.60 | $2.84 |
Enterprise Value | $18.57B | $1.38B |
Dividend Yield | 3.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McCormick & Company (MKC) trades at $51.90, down 0.35% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 8.64, net income margin of 21.91%, and consistent dividend growth. Recent Q1 2026 earnings beat expectations, while analyst consensus remains mixed with 11 buy, 17 hold, and 2 sell ratings. The pending $65 billion Unilever Foods merger and London listing plans represent significant corporate developments.
MKC presents a compelling value opportunity with attractive valuation metrics and stable profitability. The Unilever merger offers substantial growth potential but carries integration risks. Current technical weakness near support at $50-$51 creates a potential entry point for long-term investors seeking dividend income and merger upside.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
